Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright
HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $18.00 price ...
Anavex Life Sciences’ (AVXL) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 ...
H.C. Wainwright Reiterates Buy Rating on Axsome Shares
H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
bovnews15h
Vertex Pharmaceuticals Inc (VRTX) Stock’s 0.04% Increase This Year: What’s the Story?
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...
H.C. Wainwright Keeps Their Buy Rating on Disc Medicine (IRON)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.
bovnews18h
Why Did Cassava Sciences Inc (SAVA) Stock Plunge -2.83% Last Week?
Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $2.75 which represents a slight increase of $0.06 or 2.23% from the prior close of $2.69. The stock opened at $2.72 and touched ...
H.C. Wainwright Sticks to Their Buy Rating for Summit Therapeutics (SMMT)
In a report released on January 17, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research ...
Hosted on MSN11d
HC Wainwright & Co. Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy Recommendation
Fintel reports that on January 10, 2025, HC Wainwright & Co. initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) ...
Investing15d
H.C. Wainwright reiterates Neutral rating on CytomX post restructuring announcement
On Tuesday, H.C. Wainwright analysts maintained a Neutral rating on CytomX Therapeutics (NASDAQ:CTMX) following the company's announcement of a corporate restructuring and the prioritization of ...
Insider Monkey21d
BigBear.ai Holdings, Inc. (BBAI): H.C. Wainwright Boosts Price Target to $7, Citing AI Demand and Improved Financial Position
On December 30, H.C. Wainwright analyst Scott Buck raised the firm’s price target on BigBear.ai to $7 from $3 and kept a “Buy” rating on the shares. The analysts told investors in a research ...
Yahoo Finance26d
Palvella Therapeutics initiated with a Buy at H.C. Wainwright
https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-10-from-12-at-bofa H.C. Wainwright initiated coverage of Palvella Therapeutics ...
Seeking Alpha26d
RAPT upgraded at H.C. Wainwright on China licensing deal
RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...